At the news
? NEUTRALIMPACT 5/10 8-K filed Jun 2, 2026 at 08:06 ET
Medline Inc. completed a major balance-sheet restructuring on May 28, 2026, issuing $2.0B in new senior secured notes ($1.25B 5.000% notes due 2031 and $750M 5.250% notes due 2033) and refinancing its term loan facility with a new $2.75B 2033 term loan, while concurrently an equity offering of ~72.6M shares at $37/sh by selling stockholders closed. Net proceeds from the notes and term loan, plus cash on hand, were used to repay the existing 2028 term loan, refinance ~$724M of the 2030 term loan, redeem ~$500M of the 6.250% secured notes due 2029, and pay fees. The equity offering, a secondary sale by Blackstone, H&F, and ADIA affiliates, does not raise capital for the company but further monetizes sponsor stakes.
- Issued $1.25B 5.000% senior secured notes due 2031 and $750M 5.250% senior secured notes due 2033 under a new indenture dated May 28, 2026.
- Entered into Amendment No. 7 to the credit agreement, providing a new $2.75B senior secured term loan facility due May 28, 2033 (2033 Refinancing Term Loan Facility).
- Proceeds from the notes offering and new term loan, plus cash on hand, were used to repay the existing 2028 term loan in full, refinance ~$724M of the 2030 term loan, redeem ~$500M of the 6.250% Senior Secured Notes due 2029, and pay related fees.
- Certain selling stockholders affiliated with Blackstone, Hellman & Friedman, and ADIA completed an underwritten public offering of 72,554,594 shares of Class A common stock at $37.00 per share.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access